Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 72
Summary
- Conditions
- Bladder Cancer
- Lung Cancer
- Solid Tumor Cancers
- Urinary Tract Cancers
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02675829
- Collaborators
- Genentech, Inc.
- Investigators
- Principal Investigator: Alan Ho, MD, PhD Memorial Sloan Kettering Cancer Center
Get Well Soon